Female Sexual Dysfunction Affects An Estimate 84 Million Women Across The Seven Major Pharmaceutical Markets And Represents A Significant Opportunity For Investment.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c65822) has announced the addition of "Female Sexual Dysfunction sexual dysfunction Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. : Prescription Drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, Pipeline Overview 2007" to their offering. Female sexual dysfunction (FSD FSD Female Sexual Dysfunction FSD File System Driver FSD Family Support Division FSD Fire Services Department (Hong Kong) FSD Full Scale Development FSD Full Scale Deflection FSD Federal Systems Division ) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD: P&Gs Intrinsa (testosterone) is marketed in Germany, France and the UK. Scope of this title: -Comprehensive overview of the FSD pipeline with focus on clinical candidates in development for FSD -Analysis of the latest clinical trials results of FSD drug candidates in Phase we to III development -Analysis of the challenges and opportunities facing products in Phase III and above with estimates of launch dates. -Separation of drugs in development for different patient segments including hypoactive sexual desire disorder and female sexual arousal disorder Female Sexual Arousal Disorder Definition Female sexual arousal disorder (FSAD) occurs when a woman is continually unable to attain or maintain arousal and lubrication during intercourse, is unable to reach orgasm, or has no desire for sexual Highlights of this title: Despite the relatively large patient population, currently there is just one approved drug treatment for FSD. There is much unmet need among patients and physicians and consequently our belief is there is an opportunity to develop this market to parallel that of the multi-billion dollar male erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. market. While Intrinsa has benefited from first-to-market advantage, the drug suffers from several weaknesses that can be targeted by pipeline drug companies. Pipeline products can compete on safety, cost, efficiency, delivery, cosmetic elegance and reduced skin irritation skin irritation, n reaction to a particular irritant that results in inflammation of the skin and itchiness. . The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. rejection of Intrinsa for FSD has left a big gap in the market. Depending on the outcome of ongoing clinical trials, there are several appealing inlicensing opportunities for larger companies wishing to unlock the potentially lucrative US market. Reasons to order your copy: -Understand the placement of key compounds within the FSD development pipeline -Identify challenges to be met and niches to be filled in the FSD market -Assess novel mechanisms of action in the early pipeline and their potential for the treatment of FSD Contents: About Us HEALTHCARE About the Women's Health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. pharmaceutical analysis team OVERVIEW Introduction Scope of this report Pipeline overview highlights Key reasons to read this report Related reports Disclaimer For more information visit http://www.researchandmarkets.com/reports/c65822 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion